RESEARCH ON EARLY DETECTION OF CANCER & RECURRENCE
Residual Disease
When treatment for specific cancer has been completed, there is a chance that the tumor may still be present. Studies have shown that the presence of CAMLs may be indicative of residual cancer.
Detection of Recurrence
In the US, there are an estimated 20 million cancer survivors. To determine if cancer has recurred, CT imaging 2 – 3 times per year is recommended. CT scans can cause damaging radiation and requires the tumor to grow to be detected. Studies have shown that CAMLs can detect cancer recurrence before imaging, thus allowing for an earlier start of treatment.
Potential for Cancer Screening
We provide a simple blood test that potentially can screen for all cancers and in all stages.
For major cancers such as breast, prostate, lung, and colorectal, the detection rates are high in Stages I/II.